Liposomal Doxorubicin Induces PD-L1-High Tumor-Associated Macrophages and Sensitizes Triple-Negative Breast Cancer to PD-L1 Blockade
Oncology Research · 2026
DOI: 10.32604/or.2026.087138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Yu Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Doxorubicin, Triple Negative Breast Neoplasms, B7-H1 Antigen, Tumor-Associated Macrophages. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Liposomal doxorubicin (L-DOX) may alter macrophage-mediated immune regulation in triple-negative breast cancer (TNBC), but its role in programmed death-ligand 1 (PD-L1)-associated immune escape remains unclear. This study aimed to determine whether L-DOX induces a macrophage-centered PD-L1 response and affects the efficacy of PD-L1 blockade in TNBC.
Methods
Public bulk and single-cell transcriptomic datasets, bone marrow-derived macrophage models, CD8+ T-cell co-culture assays, promoter-binding analyses, and syngeneic EO771 and 4T1 TNBC mouse models were used to examine PD-L1 regulation and immune function after L-DOX treatment.
Results
The principal findings were that L-DOX preferentially induced a PD-L1-high macrophage state and sensitized TNBC tumors to PD-L1 blockade. DOX-containing therapy was associated with PD-L1 upregulation enriched in tumor-associated macrophages, and L-DOX induced stronger macrophage PD-L1 expression than free DOX or taxane-based agents. Mechanistically, L-DOX accumulation triggered DNA damage-associated ATM-p53 and cGAS-STING signaling, leading to RELA/p65-dependent NF-κB activation and PD-L1 transcription. Functionally, L-DOX-conditioned macrophages suppressed CD8+ T-cell activation, proliferation, and tumor-cell killing, whereas PD-L1 blockade restored CD8+ effector function, promoted pro-inflammatory macrophage features, and improved tumor control in EO771 and 4T1 models compared with either monotherapy.
Conclusion
L-DOX induces a PD-L1-high macrophage state with immunosuppressive features that constrains antitumor T-cell responses. Combining L-DOX with PD-L1 blockade may provide a rational chemoimmunotherapy strategy for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Thyroid Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zitieren
APA
Zheng, Y., Zheng, P., Zheng, Y., Xi, Z., & Huang, T. (2026). Liposomal Doxorubicin Induces PD-L1-High Tumor-Associated Macrophages and Sensitizes Triple-Negative Breast Cancer to PD-L1 Blockade. Oncology Research. https://doi.org/10.32604/or.2026.087138
Vancouver
Zheng Y, Zheng P, Zheng Y, Xi Z, Huang T. Liposomal Doxorubicin Induces PD-L1-High Tumor-Associated Macrophages and Sensitizes Triple-Negative Breast Cancer to PD-L1 Blockade. Oncology Research. 2026. doi:10.32604/or.2026.087138
BibTeX
@article{Zheng2026,
author = {Zheng, Yu and Zheng, Peng and Zheng, Yidan and Xi, Zihan and Huang, Tao},
title = {Liposomal Doxorubicin Induces PD-L1-High Tumor-Associated Macrophages and Sensitizes Triple-Negative Breast Cancer to PD-L1 Blockade},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2026.087138}
}
EUVIMED